BRAZIL

Image

BRAZIL

13,601,566

Total Cases

358,718

Total Deaths

12,074,798

Total Recovered

1,168,050

Total Active Cases

0

New Deaths

0

New Cases


via republicworld04/12/2021

Police in Brazil enforce coronavirus restrictions - Republic World

Stay informed with today’s latest news from India & around the world. Get all the breaking news & current Indian news on politics, sports and entertainment only on Republic World. We provide the most in-depth coverage of top national news with timely breaking of all the recent news on politics, sports & entertainment

via nbc25news04/09/2021

COVID-19 P.1. (Brazil) Variant identified in Shiawassee County - nbc25news.com

(SHIAWASSEE COUNTY, Mich. ) - The Michigan Department of Health and Human Services (MDHHS) has identified the COVID-19 variant P. 1. in a Shiawassee County resident. The P. 1. variant was first identified in Brazil. READ MORE:COVID P. 1 (Brazil) Variant identified in Genesee County. The strain was first seen in Michigan on March 31, 2021 in Bay County. This is now the sixth confirmed case of the P. 1. variant in Michigan. READ MORE: This variant has a high transmission rate.

via un.org04/08/2021

Brazilian slave labor victims learn new careers during Covid-19 | United Nations - UN News

Top Brazilian designers led a workshop earlier this year to teach victims of slave labor a new and more dignified career in fashion. The workshop is part of the "Slave Labour Never Again" project: a collaboration among the Public Ministry for Employment, the  International Labour Organization (ILO) and the University of Campinas (Unicamp). 

via pri.org04/07/2021

Brazil exceeds 4,000 daily COVID-19 deaths, India sees record infections - The World

Top of The World: For the first time on Tuesday, Brazil became the third nation to report a daily COVID-19 death rate exceeding 4,000. And, an Iranian ship identified as the Saviz was damaged by an alleged Israeli mine attack. Also, initial voting results in Greenland are in after Tuesday's parliamentary election that captured global attention.


via wionews04/03/2021

Brazil`s Rio de Janeiro extends coronavirus restrictions amid rising death toll - WION

One of the busiest cities in Brazil, Rio de Janeiro, has decided to extend the coronavirus restrictions imposed two weeks ago. The authorities have decided to extend the restrictions seeking to limit person-to-person transmission in the city. Also read | Can vaccinated people spread the virus? We don’t know, scientists say

via crainsdetroit04/01/2021

Michigan reports first case of coronavirus variant identified in Brazil - Crain's Detroit Business

LANSING — Michigan, where COVID-19 is surging more than in any state, on Thursday reported its first confirmed case of a coronavirus variant that was initially identified in Brazil. There are concerns it might affect reinfect people who have already had COVID-19. The variant was found in a…

via pri.org03/29/2021

Discussion: A deepening coronavirus crisis in Brazil - The World

Brazil — Latin America’s largest country — is experiencing a deepening crisis with the coronavirus pandemic. As part of The World's regular series of conversations about the pandemic, reporter Elana Gordon moderated a discussion with Marcia Castro, chair of the Department of Global Health and Population at the Harvard T.H. Chan School of Public Health.

via business-standard04/12/2021

Covid: Brazilian phase 3 study shows Chinas Sinovac jab has 50.7% efficacy - Business Standard

Read more about Covid: Brazilian phase 3 study shows China's Sinovac jab has 50.7% efficacy on Business-standard. The study, which was posted online and hasn't yet been reviewed by independent scientists, showed the vaccine was more effective at protecting against dangerous infections

via reuters04/08/2021

Brazil sets record daily COVID-19 death toll, Senate to probe Bolsonaro government's response - Reuters

Brazil on Thursday set a daily record of 4,249 COVID-19 deaths, with overwhelmed hospitals running low on supplies and the Senate about to open an investigation into the response of the government of President Jair Bolsonaro, who has played down the pandemic from the start.


via finance.yahoo04/07/2021

CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications - Yahoo Finance

VANCOUVER, Washington, April 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has executed an exclusive supply and distribution agreement with Biomm S.A. in Brazil. This commercial agreement will enable Biomm to sell leronlimab in Brazil following regulatory clearance. CytoDyn has committed to conduct clinical trials in Brazil for all current indications for leronlimab (i.e., Long-Hauler COVID-19, NASH and cancer). Heraldo Marchezini, Chief Executive Officer of Biomm S.A., commented, “We are very pleased with our recently executed exclusive supply and distribution agreement with CytoDyn. Our urgent goal is to provide leronlimab to Brazilians critically ill with COVID-19.” Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, “We are excited to reach this milestone for the potential benefit of Brazilian patients. Mr. Marchezini and his team have worked tirelessly to advance our commercial agreement and we look forward to a long-term relationship with Biomm. I am very grateful to Mr. Marchezini and his team for expediting our efforts to advance the availability of leronlimab for all patients who might benefit from this immune modulator product.” About Biomm S.A.Biomm's mission is to develop, produce and market global competitive biomedicines with quality and accessibility. The company's focus is developing biological products, aiming to guarantee national self-sufficiency. Due to its innovator DNA, the company is pioneer in biotechnological drugs in Brazil. Founded in 2002, Biomm’s headquarters and factory are in Nova Lima (MG), with capacity to produce 20 million of insulin per year, based on advanced and innovative technologies that guarantee the medicines quality. The company is listed on the Brazilian stock exchange (BVMF: BIOM3). For further information access www.biomm.com. About Leronlimab (PRO 140) The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using leronlimab to treat HIV and metastatic cancer. The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC). Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor important in HIV infection, tumor metastases, and other diseases, including NASH (Nonalcoholic Steatohepatitis). Leronlimab has been studied in 11 clinical trials involving more than 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients). Leronlimab is a viral-entry inhibitor in HIV/AIDS. It masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent with fewer side effects and less frequent dosing requirements than currently used daily drug therapies. Cancer research has shown CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. As a result, CytoDyn is conducting two Phase 2 human clinical trials, one in mTNBC, which was granted Fast Track designation by the FDA in 2019, and a second in a basket trial which encompasses 22 different solid tumor cancers. The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. After completing two clinical trials with COVID-19 patients (a Phase 2 and a Phase 3), CytoDyn initiated a Phase 2 investigative trial for post-acute sequelae of SARS COV-2 (PASC), also known as COVID-19 Long-Haulers. This trial will evaluate the effect of leronlimab on clinical symptoms and laboratory biomarkers to further understand the pathophysiology of PASC. It is currently estimated that between 10-30% of those infected with COVID-19 develop long-term sequelae. Common symptoms include fatigue, cognitive impairment, sleep disorders, and shortness of breath. If this trial is successful, CytoDyn plans to pursue clinical trials to evaluate leronlimab’s effect on immunological dysregulation in other post-viral syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). CytoDyn is also conducting a Phase 2 clinical trial for NASH to evaluate the effect of leronlimab on liver steatosis and fibrosis. Preclinical studies revealed a significant reduction in NAFLD and a reduction in liver fibrosis using leronlimab. There are currently no FDA approved treatments for NASH. NASH is a leading cause of liver transplant. About 30 to 40 percent of adults in the U.S. live with NAFLD, and 3 to 12 percent of adults in the U.S. live with NASH. About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn has been working diligently to refile its Biologics License Application ("BLA") for this HIV combination therapy since receiving a Refusal to File in July 2020 and subsequently meeting with the FDA telephonically to address their written guidance concerning the filing. CytoDyn expects to refile its BLA in the first half of the calendar year 2021 or shortly thereafter. CytoDyn also completed a Phase 3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension approval. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce the viral burden in people infected with HIV. Moreover, a Phase 2 clinical trial demonstrated that leronlimab monotherapy could prevent viral escape in HIV-infected patients; several patients on leronlimab’s Phase 2 monotherapy extension arm have remained virally suppressed for more than six years. There have been no strong safety signals identified in patients administered leronlimab in multiple disease spectrums, including patients with HIV, COVID-19 and Oncology. CytoDyn is also conducting a Phase 2 clinical trial with leronlimab in mTNBC, a Phase 2 basket trial in solid tumor cancers (22 different cancer indications), Phase 2 investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 Long-Haulers, and a Phase 2 clinical trial for NASH. CytoDyn has already completed two trial in COVID-19 patients (a Phase 2 and a Phase 3) and is in the process of conducting an additional COVID-19 Phase 3 trial for mechanically ventilated critically ill COVID-19 patients. More information is at www.cytodyn.com. Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to provide positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company's cash position, (ii) the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv) the Company's ability to enter into partnership or licensing arrangements with third parties, (v) the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company's ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company's clinical trials, (viii) the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company's control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release. CONTACTSInvestors: Michael MulhollandOffice: 360.980.8524, ext. 102mmulholland@cytodyn.com

via globapliancenews04/06/2021

Brazil: The President sanctions law allowing private companies to purchase COVID vaccines - GlobalComplianceNews

The Brazilian president on 10 March 2021, sanctioned Law 14.125/2021, authorizing private companies to purchase COVID-19 vaccines approved by the health regulatory agency. All doses must be reverted to the public healthcare system while priority groups are being vaccinated. After the vaccination of priority groups is completed, companies will be able to purchase the vaccines for their own use (distributing them free of charge), but 50% of the shots must still be reverted to the public healthcare system.

via yahoo04/02/2021

As Brazil becomes COVID-19 epicenter, cases rise across South America - Yahoo! Voices

As Brazil emerges as an epicenter of the coronavirus pandemic with an outbreak that is virtually unchecked, the country's regional neighbors are experiencing a worrying rise in infections. Brazil, where a more contagious variant of the novel coronavirus is circulating, saw a record 3,869 people die from COVID-19 on Wednesday, its highest single-day tally so far, according to data compiled by Johns Hopkins University. In total, the country has had more than 12.8 million confirmed cases of COVID-19, including over 325,000 fatalities.

via rioonwatch.org04/01/2021

The Fight Against Coronavirus in Brazil's Indigenous Northern Villages #Brazils Part 2—North - RioOnWatch

Clique aqui para Português This is the second article in a five-part series, published in Portuguese by favela-based online magazine Favela em Pauta and titled “Brazils: Stories of the Periphery in the Pandemic.” Each essay comes from a different region of Brazil; this one from the nation’s North. For the original article by Ariel Bentes click here. It is also our latest article on Covid-19 and its impacts on favelas.  What stories do the peripheries tell about the pandemic and inequality? This is the question we wanted to answer when we invited five journalists—residents of peripheries in each of Brazil’s five regions—to participate in this project. The idea emerged from the Coronavirus in the Peripheries Map, an initiative of the Marielle Franco Institute which registered more than 540 collectives that act on the frontlines against Covid-19, in favelas and peripheries across the country. Engaging with the data and stories of these collectives and what they have witnessed, the visions of these five journalists show that it is possible to understand the simultaneous similarities and differences of living in the different Brazils that make up Brazil.  Neglected by government and society at large, indigenous people from the states of Amazonas, Pará, Rondônia and Roraima are organizing [...]

via voanews03/27/2021

Brazil on Pace to Surpass US COVID Deaths by Year’s End - Voice of America

Brazil is averaging nearly 2,400 deaths a day from COVID-19, about one-fourth of the world’s daily tally, according to the Johns Hopkins Coronavirus Resource Center. The South American nation is on pace to reach 4,000 deaths a day, six experts told The Associated Press, a level that would rival the worst seen in the U.S., which has about one-third more people. The U.S. set a record of 4,477 deaths on January 12, 2021, according to Johns Hopkins data. "Four thousand deaths a day seems to be right around the corner," Dr.


via reuters04/08/2021

Brazil sets new daily COVID-19 death record as hospital supplies run low - Reuters

Brazil on Thursday set a daily record of 4,249 COVID-19 deaths, with overwhelmed hospitals running low on supplies and the Senate about to open an investigation into the response of the government of President Jair Bolsonaro, who has played down the pandemic from the start.

via bmj04/08/2021

Covid-19: Brazil breaks record daily death toll as crisis spreads through South America - The BMJ

Brazil recorded over 4195 deaths from covid-19 on 6 March, the highest daily record to date as the country’s health crisis showed evidence of spreading through South America Daily covid-19 deaths in Brazil have doubled since February and 90% of the country’s intensive care unit beds are occupied, with mortality increasing, according to the Oswald Cruz Foundation (Fiocruz), a research institute attached to Brazil’s Ministry of Health.1 Some regions are reporting shortages of oxygen and anaesthesia. The situation is a “huge catastrophe,” said Maragareth Portela, a senior researcher at Fiocruz. Deaths in Brazil now exceed those of the US, which was the main driver of previous waves of covid-19 in the Americas, and account for around a quarter of the global total. Sylvain Aldighieri, deputy director for the Pan American Health Organization, told The BMJ that the new high rates of hospital admissions and …

via coloradosun04/07/2021

My family in Colorado has adapted to COVID, but I worry for my Brazilian relatives - The Colorado Sun

A year ago I shared my perspective, as an immigrant, about the COVID crisis. To say that a lot has changed in the U.S. and my native Brazil since then is an understatement.  As we settled into relative isolation here, my husband lost his job when his company closed its Denver office. Fortunately, he was […]

via turnto1004/05/2021

Massachusetts leads U.S. with Brazil variant of COVID-19 after Rhode Island priest's death - Turn to 10

New data shows Massachusetts has the highest cases of the Brazil variant of COVID-19 in the United States. The Broad Institute of MIT and Harvard note that 54 cases of the variant have been reported in Massachusetts, with a majority on Cape Cod. The news follows reports of a cluster of 43 cases in Barnstable County, as well as the death of a priest serving at a Rhode Island parish who recently traveled to Brazil to care for his sick parents and brother.

via turnto1004/02/2021

Rhode Island priest dies from coronavirus in Brazil - WJAR

Members of a parish in Bristol are in mourning after their pastor died from the coronavirus. St. Elizabeth's Church posted on Facebook that the Rev. Marinaldo Batista died on Thursday in Brazil, where he was hospitalized in the intensive care unit since early March. "Father Marinaldo Batista overcame all pain and suffering and was welcomed by the angels in the final home. May God welcome you in the joy of the Kingdom," wrote the church.

via bmj04/01/2021

Covid-19: Brazil's spiralling crisis is increasingly affecting young people - The BMJ

Brazil continues to break records for all the wrong reasons as it faces its deadliest episode of the pandemic yet, amid an escalating political crisis. More than 3780 covid-19 deaths were recorded on 30 March, six days after the country recorded its 300 000th life lost to the illness. At least 60 000 Brazilians died with covid-19 in March as the more transmissible variant known as P.1 spread across the country. A flurry of high profile resignations1—including the foreign and defence ministers and the heads of the army, navy, and air force—have added to the woes of President Jair Bolsonaro. Critics hold Bolsonaro responsible for the country’s sobering covid-19 death tally, as he has played down the threat of the virus and refused to implement stricter measures to slow its spread. Now, experts have warned that covid-19 is now affecting young Brazilians …